EBV NA IgG ELISA 试剂盒
EBV NA IgG
适用: Epstein-Barr Virus (EBV)
Colorimetric
Competition ELISA
Serum
-
- 抗原 See all EBV NA IgG products
- EBV NA IgG (Anti-Epstein-Barr Virus Nuclear Antigen IgG (EBV NA IgG))
-
适用
- Epstein-Barr Virus (EBV)
- 检测方法
- Colorimetric
- 实验类型
- Competition ELISA
- 应用范围
- ELISA
- 原理
- Epstein-Barr Virus Nuclear Antigen (EBNA-1) IgG Enzyme- Linked Immunosorbent Assay (ELISA) is intended for the qualitative and semi-quantitative determination of IgG antibody in human serum to EBNA-1 recombinant antigen.
- 样品类型
- Serum
- Analytical Method
- Qualitative and Semi-Quantitative
- 特异性
- 100%
- 灵敏度
- 97.8 %
-
-
- 样本量
- 100 μL
- 实验时间
- 1 h
- 板类型
- Pre-coated
- 限制
- 仅限研究用
-
- 储存条件
- 4 °C
- 有效期
- 18 months
-
- 抗原 See all EBV NA IgG products
- EBV NA IgG (Anti-Epstein-Barr Virus Nuclear Antigen IgG (EBV NA IgG))
- 别名
- Epstein Barr Virus Nuclear Antigen (EBNA) IgG (EBV NA IgG 产品)
- 物质类
- Antibody
- 背景
-
Epstein-Barr virus (EBV) is a common human pathogen, affecting 80% of adults in the US. Since the discovery of Epstein-Barr virus in 1964, EBV has been etiologically implicated in an increasing number of human diseases, such as infectious mononucleosis, Burkitt's lymphoma and nasopharyngeal carcinoma. EBV has also been associated with B cell lymphomas in immunosuppressed individuals, including both transplant patients and patients with AIDS. EBV is classified as a member of the herpesvirus family based upon its characteristic morphology. All herpesviruses share the ability to establish a latent infection in their hosts. Although primary infection with EBV during childhood is usually asymptomatic, nearly one-half to two-thirds of primary infections with the virus in older adolescents and young adults result in overt clinical disease such as infectious mononucleosis (IM). Infectious mononucleosis is an acute, self-limited lympho-proliferative disease caused by EBV. When primary infection is delayed until young adulthood and adolescence, however, there is about a 50% chance that it will occur with the classic clinical manifestations associated with IM.
Infection of the target cells leads to two forms of viral cycles: 1) latent, nonproductive and 2) productive, replicative infections. In both cycles, one of the earliest antigens expressed is lymphocyte-detected membrane antigen, a cell-surface antigen recognized by T-cells. It has been well established that most individuals exposed to EBV develop a heterophile antibody response. Expression of EBNA-1 either follows or parallels membrane antigen at 12 to 24 hours post infection. EBNA-1 is found as nonstructural, intranuclear antigen(s), present in all EBV-transformed cell lines as in tumors from Burkitt's and nasopharyngeal carcinoma patients. In the fully productive, replicative cycle, the synthesis of antigen follows EBNA-1. The viral capsid antigen complex (VCA) appears late in the replicative cycle. It has recently become apparent that EBNA-1 is probably not a single antigenic moiety, but a multicomponent antigen complex, on the basis of reactivities of sera from different classes of patients. The major component EBNA-1 has been purified and sequenced in its entirety.
Antibody levels of EBNA-1 IgG, are diagnostic in determining acute and convalescent stages in IM. IgG antibodies to EBNA-1 are rarely present in acute IM and rise during convalescence. They will rise to a plateau level in three months to a year and will normally persist for life. The DAI EBNA-1 IgG kit utilizes the ELISA technology where a purified recombinant EBNA-1 antigen is bound to the wells of a microplate. A peroxidase coupled anti-human IgG conjugate is used as the detection system.
-
You are here:
